posit bia head result
messag earn preview focu stock biotech
coverag report product sale increment posit bias
group head earn follow mix result market weak
overal think neutral neutral neutral buy
bgne buy gwph buy neutral neutral buy
well posit rel expect expect neutral buy
buy neutral celg neutral buy perform line
increment posit bias head earn follow mix result
market weak stock btk gave roughli
half gain btk follow mix earn result partial due
patter significantli under-perform broader market biotech
btk still ytd vs consolid categori
continu potenti provid continu tailwind small mid-siz innov
earn could potenti provid increment catalyst group view
except stock cover seem trade closer respect
week low rather high see figur street consensu revenu estim
remain rel unchang see figur overal think
buy neutral neutral buy well posit rel
investor expect head earn expect neutral
buy buy neutral celg neutral buy perform in-
line visibl lower buy neutral buy
celg revenu figur bn
page analyst certif import disclosur
neutral focu tibsovo launch trajectori investor await
updat later year share under-perform
vs btk despit two posit data point tibsovo claridhi result
cholangiocarcinoma us approv line aml investor concern arisen
follow weak tibsovo sale updat mtap
program indic need explor altern dose schedul strong tibsovo
growth model sale vs bloomberg consensu could
potenti remov small overhang stock management note strong volum growth
march april
bgne buy focu china commerci roll-out us regulatori submiss
year strong sale growth bgne current market product abraxan
revlimid vidaza acquir celg could potenti provid increas investor
confid bgne commerci capabl china model growth
product sale vs follow season
growth respect bgne continu improv market access drug
china inclus national/provinci reimburs drug list well label
extens abraxan supplement import drug applic metastat pancreat
cancer accept nmpa
celg neutral otezla sale perform could investor interest
follow recent divest request ftc otezla significantli
miss street consensu like due step-up manufactur liabil
patient medicar part coverag gap doughnut hole celg account
guidanc accord management suggest strong rebound sale
street consensu growth vs expect increment pipelin
updat key pipelin asset ozanimod fedratinib luspatercept liso-cel
buy updat esmo next investor worri rubraca
commerci potenti persist worri competit posit rubraca
ovarian cancer continu weigh stock competitor move first-lin
mainten therapi continu heavili invest potenti long-term label
extens opportun parp inhibitor file prostat cancer guid
rubraca sale forecast vs in-lin street
buy expect continu cabometyx growth rcc
season miss slightli miss street consensu sequenti
growth driven volum price growth off-set
increas gross-to-net price adjust inventori decreas
inventori low end histor rang potenti lower gross/net
growth rx demand believ set well potenti beat
set year margin expans per manag guidanc
growth jakafi sale growth oper expens opting-
co-fund olumi develop similar oncolog product jakafi
disproport affect doughnut hole liabil recent re-affirm
guidanc indic re-bound histor strongest
jakafi street expect yoy jakafi growth vs underli
volum trend strong recent quarter previous note expect
major jakafi growth come volum oppos price action
includ current approv indic mf pv well contribut
neutral expect low beat enough increas investor
confid follow disappoint earn expect nerlynx sale
decreas substanti despit price increas jan us
nerlynx sale declin vs due multipl factor includ increas
discontinu rate increas gross-to-net adjust oper issu
commerci sale forc said think even potenti sale beat vs street
consensu total revenu enough remov investor concern around
nerlynx growth potenti given increasingli competit market dynam
page analyst certif import disclosur
earli breast cancer market well superior clinic data put forth
competitor metastat breast cancer set eg dsnki
buy focu adcetri growth new indic upcom pipelin
updat adcetri sale miss street consensu growth vs
due typic season purchas pattern januari accord
manag indic sequenti growth februari march april
re-affirmed adcetri product sale guidanc remain
confid adcetri main growth driver line hodgkin lymphoma hl
peripher cell lymphoma indic given increas promot effort
also recent updat nccn treatment guidelin chl longer term believ
upsid stock predominantli come pipelin updat includ
top-lin result pivot studi tucatinib inhibitor breast
cancer initi data studi like esmo combin enfortumab vedotin
ev agent previous untreat bladder cancer patent
think commentari thing result like import driver
perform view
buy eye onpattro launch enrol on-going trial
face tafamidi estim revenu line consensu
primarili driven increas sale onpattro on-going global launch
expect investor focu remain onpattro launch attr market dynam
particularli competit color impact tafamidi thu far well
enrol alni attr-cm trial continu think near term onpattro number
achiev longer term competit headwind price
pipelin expect givosiran also topic discuss ahead potenti launch
patient number launch prep price lumasiran given recent competit
updat thought upcom pivot data readout
buy await meet fda estim revenu
in-lin consensu driven steadi growth naglazym vimizim
palynziq well modest price increas though continu
low-end palynziq launch remain cautiou market opportun
expect investor focu remain valrox specif compani pre-submiss
meet fda ema timelin acceler approv still
move forward full blast acceler file strategi provid updat
follow pre-submiss meet us/eu also expect increas
focu vosoritid near ye pivot updat though continu think
question vosoritid competit landscap could limit upsid
near term
buy expect continu interest galafold growth gene therapi
estim revenu line consensu repres
growth revenu net new pt global galafold
compani guid fabri patient drug
think achiev expect discuss continu focu us dynam
newli launch geographi look pipelin expect discuss
focu larg upcom gene therapi readout expect particularli
given time recent rais compani collabor effort
gene therapi front also listen enrol updat compani
on-going trial at-gaa pomp
buy busi stabil await game forecast
revenu vs consensu driven taf strength symphoni
data may end indic stabil hepat portfolio think
investor focu continu potenti given still strong cash
posit broader strategi compani new ceo daniel day
helm particularli nash space see thought said wed note
co guid provid color long-term vision later year also
look updat filgotinib discuss fda potenti file timelin
financi gilead plan adjust guidanc follow selonsertib result
filgotinib file plan continu think gilead remain attract valu
page analyst certif import disclosur
base busi stabil appear justifi valuat even exclud pipelin
opportun risk/reward skew upsid
neutral expect investor focus reimburs progress
eu progress earlier stage pipelin estim revenu
slightli consensu estim cf think focu
continu reimburs discussions/progress eu though assum
get resolv model well upcom tripl launch pipelin
think discuss also focu compani recent activ gene therapy/
edit space dmd see thought next steps/timelin associ
program beyond well also listen updat earli stage
fsg program well commentari hemoglobinopathi studi
time data updat competit landscap develop collabor
yatin suneja coverag neurolog inflamm coverag
neutral expect top/bottom line beat continu good perform
complement franchis metabol continu laggard
forecast complement franchis sale come slightli street consensu
driven continu robust uptak gmg assum q/q patient growth
vs modest q/q growth core pnh ahu indic
benefit one extra infus day quarter worth believ
transit soliri ultomiri progress faster expect result
soliri sale come slightli consensu ultomiri sale come ahead
consensu forecast metabol portfolio come line street consensu
q/q y/i new price strategi surround weight-
base dose regimen go provid headwind throughout
neutral rebound ms franchis drive upsid spinraza growth
moder sale modestli street biosimilar well
expect report revenu consensu
q/q y/i estimate rebound ms
franchis follow soft spinraza global sale like come modestli
consensu expect out-performance biosimilar mainli driven imraldi
bottom line believ consensu non-gaap ep readili achiev
leverag opex
gwph buy epidiolex pois anoth strong quarter european approv
decis come soon gwph report solid epidiolex sale beat
vs street expect anoth solid quarterli perform drug
analysi data symphoni health iqvia suggest continu growth
momentum even use conserv assumpt arriv
sale vs consensu view epidiolex sale like need come
beat high investor expect
neutral ingrezza sale like consensu wont make
lack n-t catalyst histor third parti data less reliabl predict
ingreza sale like snap back season weak could come
q/q ahead street estimate q/q
q/q respect meanwhil partner drug orilissa
slow start though maintain guidanc sale year
earn call model royalti payment impli
total sale base slow trajectori launch far
believ like come slightli estim though line
consensu estim impli sale
neutral expect signific beat dupix eylea
come least line expect eylea sale come least in-lin
consensu though upsid possibl uptak recent approv diabet
retinopathi indic weekli dupix reach all-tim high
like fuel robust uptak recent approv indic asthma adolesc
atop dermat expect signific beat dupix
page analyst certif import disclosur
vs consensu estim meanwhil im data suggest uptick
praluent weekli q/q sale like come street
estimate kevzara weekli q/q though sale track in-lin
consensu final limit visibl libtayo given first-in-class label
cutan squamou cell carcinoma limit option demand robust
consensu appear achiev
page analyst certif import disclosur
figur quarter quarter chang consensu estim total revenu
page analyst certif import disclosur
neutral focu tibsovo launch trajectori investor await mtap updat later year
takeaway under-perform market vs btk despit two posit datapoint tibsovo claridhi result
aml approv investor concern arisen follow weak tibsovo sale clinic updat mtap program indic need
explor altern dose schedul strong tibsovo sale could potenti remov small overhang stock
compani report factset consensu guggenheim secur llc estim
forecast revenu includ tibsovo sale line street consensu
investor focu remain tibsovo launch trajectori follow revenu miss vs estim result qoq declin
tibsovo sale management cite factor includ increas free drug program use post-deduct reset lower inventori build
follow recent snda approv tibsovo slightli broader-than-expect frontlin aml patient popul expect investor interest
potenti effect tibsovo demand first three potenti newli diagnos aml market segment
initi dose escal data present later year preclin data present seem suggest need
combin drug taxan agent singl agent activ may difficult detect all-com trial format due small number
patient given tumor histolog link dinner note
announc tibsovo met primari endpoint ph claridhi trial treatment cholangiocarcinoma data come esmo
snda file track year-end
remain neutral-r think upsid potenti stock current valuat larg tie pipelin potenti particularli success
inhibitor visibl agent opportun still low view given earli develop stage mechanist
intrigu think credit like reflect stock first clinic respons gener initi ph dose escal data guid
page analyst certif import disclosur
buy eye onpattro launch enrol on-going trial face
takeaway estim revenu line consensu primarili driven increas sale onpattro on-going global
launch expect investor focu remain onpattro launch attr market dynam particularli competit color impact tafamidi thu far
well enrol alni attr-cm trial continu think near term onpattro number acheivebal longer term competit headwind
price pipelin expect givosiran also topic discuss ahead potenti launch patient number launch prep price
lumasiran given recent competit updat thought upcom pivot data readout
compani report factset consensu guggenheim secur llc estim
forecast sale larg line consensu repres growth recal last quarter total
patient commerci onpattro new start form management guid continu steadi growth quarter quarter
recal compani ceas report start metric beyond provid color domest demand overal market dynam
forecast opex expenditur vs consensu varianc owe greater estim expens vs
street recal compani guid non-gaap expens non-gaap sg expens
year cash share outstand end
dilut ep estim slightli street dilut ep
wed note beat ep last quarter beat miss
expect major investor discuss focu onpattro domest sale well ou launch initi ph apollo-b trial patisiran
wt/h-attr-cm patient helios-a/b trial subcutan vutrisiran
also expect see investor focu file givosiran potenti launch earli us/eu follow approv addit
also set report top-line data lumasiran ph trial illuminate-a later year
clinic program trial readout later year could also focu call includ aatd initi data ph studi
initi ph data aln-agt studi hypertens
longer term outlook remain buy-rat think near term onpattro number achiev competit risk tafamidi price
level encourag compani expand pipelin preclin engin
page analyst certif import disclosur
takeaway expect top/bottom line beat continu good perform complement franchis metabol continu laggard
compani report factset consensu guggenheim secur llc estim
earn follow good expet revenu come street estim non-gaap
ep also like beat consensu estim given opex leverag
complement franchis perform well sale like ahead consensu forecast complement franchis sale come slightli
street consensu driven continu robust uptak gmg assum q/q patient growth vs modest q/q growth
core pnh ahu indic benefit one extra infus day quarter worth believ transit soliri
ultomiri progress faster expect result soliri sale like come slightli consensu ultomiri sale come ahead
consensu recal pnh patient convert soliri ultomiri launch
assum pnh convers rate continu progress per month rate would expect pnh patient convert
soliri end addit ultomiri market two quarter mani patient alreadi move larger mainten dose
level also result slightli higher sale thu given like larg number new patient assum averag pnh
patient ultomiri vs slightli larger per-pati revenu patient mainten dose view ultomiri sale
rang like vs consensu overal believ total complement franchis sale could come q/q y/i vs
estim consensu q/q y/i q/q y/i respect
metabol portfolio perform line forecast metabol portfolio come line street consensu q/q y/i
new price strategi surround weight-bas dose regimen go provid headwind throughout
fx provid headwind top-line usd modestli appreci vs currenc note ex-u revenu
hedg impact like minim
ultomiri ultomiri regulatori file ahu accept prioriti review could like result approv around octob pdufa
date would expect ultomiri adopt rate ahu similar pnh phase trial nmosd slate begin toward
fcrn antibodi continu progress phase i/ii trial initi phase ii/iii trial waiha mg pv
longer term outlook remain neutral-r base view current valuat adequ captur lack near-term growth
pipelin rel defens commerci posit embodi ultomiri launch
page analyst certif import disclosur
bgne buy focu china commerci roll-out us regulatori submiss
takeaway sale growth bgne current market product abraxan revlimid vidaza acquir celg could potenti provid increas
investor confid bgne commerci capac china continu expect investor predominantli focu pipelin updat includ upcom
zanubrutinib tislelizumab approv decis china us pivot trial result well progress toward regulatori submiss us
compani report factset consensu guggenheim secur llc estim
forecast revenu product sale collabor revenu street consensu
declin revenu vs primarili due assumpt decreas collabor revenu vs celg
model growth product sale vs follow season growth respect bgne continu
improv market access drug china inclus national/provinci reimburs drug list well label extens abraxan
supplement import drug applic metastat pancreat cancer accept nmpa
china nda zanubrutinib mcl cll tislelizumab chl remain regulatori review decis guid
us top-lin result random cohort zanubrutinib phase aspen trial guid nda file anticip late
top-lin result us pivot phase ii trial tislelizumab liver cancer guid
remain buy-rat bgne potenti upsid view tie set regulatori well pipelin mileston compani continu
aggress expand portfolio oncolog drug take advantag fulli integr global biotech platform
page analyst certif import disclosur
neutral expect top/bottom-lin investor focu remain potenti activ
takeaway rebound ms franchis drive upsid spinraza growth moder sale modestli street biosimilar well
compani report factset consensu guggenheim secur llc estim
earn expect report revenu consensu q/q y/i estimate
rebound ms franchis follow soft bottom line believ consensu non-gaap ep readili achiev leverag opex
ms portfolio follow season weak q/q im script data suggest rebound q/q overal ms market note
ms franchis sale impact inventori drawdown thu assum similar level re-stock coupl histor
stronger expect biib ms franchis sale come around street estim
spinraza recal despit q/q increas number patient therapi sale mainli due season less complianc
mainten dose averag dose vs expect trend revers assum modest uptick averag mainten
dose patient start believ sale could come line q/q eu sale benefit price adjust franc
shipment time per manag meaning given dynam expect ex-u sale q/q come closer
overal global sale like line q/q modestli consensu q/q
biosimilar limit visibl expect line result benepali/flixabi believ imraldi success launch continu sale come
closer q/q vs street q/q overal estim biosimilar sale q/q vs street q/q
longer term outlook remain neutral-r recent setback alzheim competit sma dynam intrigu distant pipelin
page analyst certif import disclosur
mm diff gscon diff gscon diff gscon diff gscon diff avonex royalti q/q oper q/q inventori impact estimate salesest ex-u sale vs initi gs estimate vs drawdown drawdown ms royalti exclud fampyra estim gener salesoveral sec file factset guggenheim secur llc analysi rx data base im ms franchis drug q/q ww sale predict vs gs model street drawdown
neutral await meet fda
takeaway estim revenu in-lin consensu driven steadi growth naglazym vimizim palynziq well
modest price increas though continu low-end palynziq launch remain cautiou market opportun expect investor focu
remain valrox specif compani pre-submiss meet fda ema timelin acceler approv still move
forward full blast acceler file strategi provid updat follow pre-submiss meet us/eu also expect increas
focu vosoritid near ye pivot updat though continu think question vosoritid competit landscap could limit
upsid near term
compani report factset consensu guggenheim secur llc estim
forecast sale roughli in-lin consensu though slightli consensu kuvan vs street slightli
palynziq vs street dilut ep estim compar street dilut ep
believ investor focu remain palynziq launch pipelin program remain low end palynziq estim remain cautiou
market opportun daili subq product assum patient grow penetr fulli reimburs patient compar
reimburs patient
in-lin consensu term vimizim naglazym sale
note price increas januari aldurazym march naglazym firdaps vimizim kuvan
beat ep last quarter beat in-lin
expect major investor discuss focu valrox includ potenti phase design consider time pre-submiss meet
progress toward put packag togeth acceler approv also listen new analysis/theori explain varianc
phase phase result
also expect increas focu vosoritid given compani expect data said think upsid near term program
rel limit wed note competit landscap get crowd recent acquir therachon compani develop
achondroplasia current enrol patient phase studi well natur histori studi ascendi pharma held day june
discuss preliminari phase trial design initi bridgebio/q enter phase trial
anticip result also initi observ studi
clinic program trial initi includ bmn pku potenti bmn friedrich ataxia decis file
model updat adjust aldurazym estim adjust time shipment maintain neutral rate
longer term outlook remain neutral-r continu think near-term option price struggl see could surpris
upsid continu believ competit updat hemophilia achondroplasia could repres headwind
page analyst certif import disclosur
celg neutral otezla perform could focu follow recent divest request ftc
takeaway recent ftc request divest otezla clearli came surpris street result delay acquisit
celg/bmi seek buyer otezla perform could potenti increas investor import head earn expect increment
pipelin updat key pipelin asset ozanimod fedratinib luspatercept liso-cel
compani report factset consensu guggenheim secur llc estim
forecast revenu opex dilut ep compar street consensu respect
product level sale estim net sale revlimid pomalyst otezla abraxan versu street estim
respect
ozanimod nda multipl sclerosi fedratinib nda myelofibrosi luspatercept nda file beta thalassemia myelodysplast syndrom md
accept current fda review
top-line result pivot trial liso-cel transcend-nhl karmma guid year end file guid
respect recent multipl myeloma/anti-bcma deep dive
januari celg also guid toward clinic data updat anti-bcma t-cell engag mab
june celg bgne mutual agre termin global collabor antibodi tislelizumab
modifi abraxan sale post-lo reflect steeper sale eros
given pend acquisit remain neutral-r celg current share price offer littl upsid potenti given acquisit offer
cash share conting valu right cvr
page analyst certif import disclosur
buy updat esmo investor worri rubraca commerci potenti
takeaway worri competit posit rubraca ovarian cancer continu weigh stock competitor move first-lin
mainten therapi continu heavili invest potenti long-term label extens opportun parp inhibitor file prostat cancer guid
compani report factset consensu guggenheim secur llc estim
rubraca sale forecast vs in-lin street consensu
investor still question sustain recent rubraca growth potenti impact recent approv lymparza azn first line brca
recent commerci launch rubraca germani uk march could potenti tailwind rubraca sale
beyond ovarian cancer expect much investor discuss focu potenti competit posit rubraca prostat cancer
upcom updat esmo well line extens opportun indic parp inhibitor potenti includ prostat
urotheli breast pancreat cancer
remain buy-rat base view current valuat doesnt adequ reflect rubraca commerci potenti across variou
cancer type well posit address variou partner longer term
page analyst certif import disclosur
buy investor look continu growth rcc season miss
takeaway model product sale vs consensu reflect sequenti qoq sale iqvia growth
remain single-product stori albeit growth potenti via indic expans opportun maintain buy pt
compani report factset consensu guggenheim secur llc estim
investor continu uncertain growth sustain given earn miss competit dynam rcc
estim product sale vs consensu consist sale qoq broken
rcc qoq qoq cometriq sale qoq estim base iqvia actual
estim gross-net captur rate adjust result qoq demand
season headwind high gross-net adjust due payer mix inventori decreas low-end histor level potenti mitig
stock remain single-product stori albeit consider growth potenti via indic expans opportun
on-going ph trial rcc opdivo result opdivo yervoy initi
on-going ph trial combin tecentriq random vs nexavar bayri initi
ph differenti thyroid carcinoma initi repres potenti sourc upsid estim
signal-find trial could gener addit go-phas decis potenti bladder lung cancer
updat near-term estim account updat iqvia script data cabometyx pt remain
remain buy-rat base view stock remain fundament well-posit given statu prefer tki rcc
despit shift landscap near-term growth opportun long-term expans opportun signal-find phase ib
page analyst certif import disclosur
buy expect continu interest galafold growth gene therapi
takeaway estim revenu line consensu repres growth revenu net new
patient global galafold compani guid fabri patient drug think achiev expect
discuss continu focu us dynam newli launch geographi look pipelin expect discuss focu larg upcom
gene therapi readout expect particularli given time recent rais compani collabor effort gene therapi front
also listen enrol updat compani on-going trial at-gaa pomp
compani report factset consensu guggenheim secur llc estim
forecast galafold sale vs consensu repres growth
report prescript referr form prf prescrib galafold april compani continu guid
patient patient global apr
manag comment consist galafold adopt trend order pattern previou year quarter-over-quart revenu growth
trend like non-linear higher growth year
model opex expenditur vs consensu varianc owe lower estim expens vs street
wed highlight cog galafold percentag net sale vs prior year period report
cog percent revenu favor galafold revenu subject lower royalti
dilut ep estim slightli street dilut ep
wed note beat last quarter miss beat
expect signific amount focu upcom data readout fold lead gene therapi program recal compani plan
present two-year result patient studi also listen updat progress earlier stage cln
program in/mov toward clinic
pipelin mover includ updat preclin poc fabri pomp diseas gene therapi expect public meet
throughout year intend select pomp aav gene therapi clinic candid move ind-en studi year
compani also present addit data at-gaa studi
also continu look forward updat fold/upenn collab new gene therapi lsd rare diseas
longer term outlook remain buy-rat expect galafold launch continu perform well at-gaa expect appropri set
point believ thing combin compani emerg gene therapi focu lead upsid
page analyst certif import disclosur
buy busi stabil await game
takeaway forecast revenu vs consensu driven taf strength symphoni health data may end indic
stabil hepat portfolio think investor focu continu potenti given still strong cash posit broader strategi
compani new ceo daniel day helm particularli nash space see thought said wed note compani guid
provid color long-term vision later year also look updat filgotinib discuss fda potenti file timelin
financi gilead plan adjust guidanc follow selonsertib result filgotinib file plan continu think gilead remain attract valu
base busi stabil appear justifi valuat even exclud pipelin opportun believ risk/reward skew upsid
compani report factset consensu guggenheim secur llc estim
estim revenu vs consensu continu think taf grow driven growth biktarvi vs consensu
descovi vs consensu though note recent manag commentari cannib genvoya vs
hbv hcv prescript trend april may suggest stabil hbv product trx/trx basi
hbv hcv product respect
recent generic ranexa vs consensu letairi vs consensu prescript trend indic sharp declin
ranexa sequenti letairi sequenti
opex estim consensu though note remov selonsertib estim
gilead intend updat guidanc quarter call adjust selonsertib filgotinib
wed note beat non-gaap ep last quarter beat
think filgotinib key focu point call particular look updat request fda discuss potenti file
time manta studi remain potenti rate-limit step file us on-going manag provid updat
timelin europ compani expect file ema expect data sjogren syndrom cutan lupu
erythematosu
hiv file snda descovi prep april anticip review time month approxim oct advisori
committe meet schedul august wed note potenti increas headlin risk around truvada prep presidenti hope senat
page analyst certif import disclosur
kamala harri mr beto orourk senat kristen gillibrand though dont expect meaning impact share near-term
compani also expect phase data earlier stage candid
nash becom wait-and-se atla combin studi top-lin data expect determin potenti go-forward combin
addit recent competitor confer mr oday note time need paus kind reconsid option invest
strategi program place get decis point cours year earli next year
hematology/oncolog provid updat academ confer throughout compani also plan initi allogen kte-
hbv expect data phase studi
adjust hiv ranexa letairi sale ahead result name expect cannib genvoya biktarvi launch
continu adjust ranexa letairi sale base prescript trend pt remain
remain buy-rat base continu view base busi posit well taf launch prep tailwind
predict hcv new ceo daniel day strategi thu far appear larg unchang anticip discuss long-term strategi
vision later year follow broader strateg review think bar rel low sentiment shift/upsid
page analyst certif import disclosur
takeaway gwph expect anoth solid quarter epidiolex sale like need come beat high investor expect
compani report factset consensu guggenheim secur llc estim
gwph report solid epidiolex sale beat vs street expect anoth solid quarterli perform drug
analysi data see symphoni health iqvia suggest continu m/m growth script though might see paus june
script data predict m/m declin estim full data avail nonetheless even use conserv assumpt arriv
sale estim support compani commentari indic patient take epidiolex end
even q/q growth would annual sale view epidiolex sale like need
come beat high investor expect epidiolex util weight-bas dose compani sever month launch
mani patient may titrat higher dose coupl increas older heavier patient get drug may translat even higher
sale figur may off-set lack eap/ol bolu seen previou quarter patient finish transit commerci product
posit chmp opinion epidiolex expect shortli approv like come follow launch franc germani uk
manag intern research suggest high level interest epidiolex price like discount price
follow posit pivot data tuber sclerosi snda target note common seizur type
patient focal seizur suggest data could dramat expand epidiolex label address epilepsi popul
longer term outlook remain buy-rat gwph base posit view continu epidiolex launch european market
page analyst certif import disclosur
gwph plc diff gscon diff gscon diff gscon diff gscon diff epidiolex oper m/m m/m sale mm report gwphsourc sec file guggenheim secur llc analysi rx base ims/sh estimatesv consensu
takeaway set year margin expans per manag guidanc growth jakafi sale growth
oper expens found inci convict continu jakafi growth across exist indic despit potenti new/first competitor
myelofibrosi mf market given celg fedratinib pdufa date sept expect investor focu pipelin updat street continu look
progress toward ad addit commerci product portfolio
compani report factset consensu guggenheim secur llc estim
forecast revenu line consensu higher opex vs thu lower dilut ep vs
product level line consensu model jakafi sale vs iclusig sale vs
note expect major jakafi growth come volum oppos anticip price action includ
current approv indic mf pv well contribut recent approv agvhd
top-line data cholangiocarcinoma guid nda file track year end
data updat graft-versus-host diseas gvhd program includ ph result evalu jakafi steroid-refractori acut gvhd ph
result evalu jakafi steroid-refractori chronic gvhd track
regulatori meet set initi pivot ph vitiligo program topic ruxolitinib follow posit ph ii top-line data link
remain buy-rat base view remain addit upsid potenti vs street consensu particularli topic ruxolitinib
vitiligo atop dermat
page analyst certif import disclosur
neutral ingrezza sale like consensu wont make lack n-t catalyst
takeaway ingrezza sale come ahead consensu fda meet phase trial adult expect shortli trial start shortli thereaft
compani report factset consensu guggenheim secur llc estim
ingrezza ingrezza sale q/q impact season weak higher gross-to-net medicar donut hole plan chang
etc like revers season strong quarter industri histor third parti data less reliabl
captur script script growth trend entir correl compani report number note symphoni health
q/q iqvia q/q show nice uptick q/q growth email us ingrezza rx tracker one assum
q/q growth conserv translat captur rate actual sale growth would impli ingrezza sale
call management note headwind less account headwind histor stronger believ ingrezza
sale could come q/q ahead street estimate q/q q/q respect
orilissa recal receiv royalti nc net sale orilissa current approv endometriosi
earn call manag note much slower ramp previous anticip maintain initi guidanc
year report royalti payment suggest total orilissa sale base royalti model royalti
payment impli total sale base slow trajectori launch far believ like come slightli
estim though line consensu estim impli sale
follow posit phase ii proof concept data congenit adren hyperplasia plan meet fda determin
develop path endpoint pivot program registr program adult patient phase iia trial pediatr patient
plan begin pend regulatori discuss pivot phase trial adult commenc
call expect updat opicapon nda submiss treatment motor fluctuat parkinson patient snda orilissa
treatment uterin fibroid expect file
voyag januari enter partnership nc develop gene therapi program
compani expect present extend durabl data one asset vy-aadc parkinson expect updat call
longer term outlook remain neutral-r base limit increment growth opportun ingrezza lack meaning near-term
page analyst certif import disclosur
neutral investor regain confid
takeaway follow disappoint earn expect nerlynx sale come substanti product struggl find place
increasingli competit breast cancer market earn call could potenti provid insight pbyi-fda discuss regard
nala metastat bc fileabl well regulatori path forward summit tumor basket
compani report factset consensu guggenheim secur llc estim
forecast revenu includ nerlynx sale street consensu
investor still question nerlynx growth potenti given increasingli competit market dynam earli breast cancer market well
superior clinic data put forth competitor metastat breast cancer market dsnki
despit price increas jan us nerlynx sale declin vs due patient termin therapi upon
complet year nerlynx treatment approv label increas discontinu rate decreas util follow dose delay
modif increas gross-to-net adjust higher-than-averag vacanc rate sale forc result sale territori
sale rep point
guid file snda nerlynx mbc base recent present nala trial link summer
addit data summit trial expect per management guidanc addit guid meet fda discuss
clinic develop regulatori strategi summit trial
remain neutral-r base cautiou view regard growth prospect nerlynx within breast cancer market given
evolv market dynam increas competit believ factor obscur nerlynx place within treatment paradigm
page analyst certif import disclosur
neutral expect signific dupix eylea come least in-lin
takeaway dupi continu deliv eylea like maintain resili though see limit growth potenti libtayo inflect like nsclc
data read praluent kevzara yet see inflect
earn expect eylea sale come least in-lin consensu though upsid possibl uptak recent approv indic diabet
retinopathi note manag previous comment go take time develop market modest normal inventori recal
slight draw-down weekli dupix reach all-tim high like fuel robust uptak recent approv indic
asthma adolesc atop dermat drive q/q growth expect signific beat dupix vs consensu
estim meanwhil im data suggest uptick praluent weekli q/q sale like come street estimate note
new price dynam lower price increas rebat like keep upsid check impact recent addit cvot claim praluent label
yet materi kevzara weekli q/q though sale track in-lin consensu final limit visibl libtayo given
first-in-class label cutan squamou cell carcinoma limit option demand robust consensu appear achiev
long term outlook remain neutral-r moder sale key drug eylea well failur follow-on drug kevzara praluent
take compani intrigu pipelin realiz commerci success still somewhat distant
page analyst certif import disclosur
diff gscon diff gscon diff gscon diff gscon diff eylea ex-u oper sec file factset guggenheim secur llc sale base recent script trend q/q initi gs estimate street estimate vs gsv streetg commentseylea limit visibl though consensu appear achiev expect modest benefit inventori new indic asthma adolesc ad approv fuel substanti q/q growth expect solid consensu expect new price dynam moder data show nice uptick impact new label cvot claim yet limit visibl consensu achiev sec file factset guggenheim secur llc analysi rx data im estim
buy focu adcetri growth new indic upcom pipelin updat
takeaway uptak adcetri line chl line slower previous expect believ upsid stock predominantli
come key pipelin updat includ top-lin result pivot studi tucatinib inhibitor breast cancer initi data ev-
studi combin enfortumab vedotin agent treat bladder cancer
compani report factset consensu guggenheim secur llc estim
forecast adcetri sale growth vs street consensu
adcetri sale miss street consensu sin season adcetri grew vs
re-affirmed adcetri product sale guidanc remain confid adcetri main growth driver line hodgkin
lymphoma hl peripher cell lymphoma indic given increas promot effort recent updat nccn treatment guidelin
bla file enfortumab vedotin post-cpi treat bladder cancer guid year base data recent present link first
result sgen first-lin bladder cancer studi may present upcom esmo confer per management commentari
expand tucatinib phase trial complet enrol patient top-lin result guid
partnership program includ belantamab mafadotin bcma-adc gsk polatuzumab vedotin read-out pivot
studi trial polarix trial respect pl see recent bcma deep dive
remain buy-rat base posit view upsid potenti compani proprietari partner pipelin
page analyst certif import disclosur
neutral expect investor focus reimburs progress eu
progress earlier stage pipelin
takeaway estim revenu slightli consensu estim cf think focu continu reimburs
discussions/progress eu though assum get resolv model well upcom tripl launch pipelin think discuss
also focu compani recent activ gene therapy/edit space dmd see thought next steps/timelin associ
program beyond well also listen updat earli stage fsg program well commentari hemoglobinopathi
studi time data updat competit landscap develop collabor crsp
compani report factset consensu guggenheim secur llc estim
forecast cf sale slightli consensu vs street lower kalydeco vs consensu
orkambi vs consensu higher symdeko vs current forecast total cf sale year vs
street estim
compani guid combin non- sg expens combin sg expens
forecast total opex vs street non-gaap tax rate guidanc remain
non-gaap dilut ep estim larg in-lin street non-gaap dilut ep
wed note beat last quarter beat beat
expect focu potenti initi data updat vrtx/crsp hemoglobinopathi program meet later year
focu may also initi data dose rang studi acut pain bunionectomi year well progress
potenti fsg candid clinic later year
discuss around new effort dmd also interest follow vrtx acquisit exon therapeut extend collabor
crsp addit well listen commentari braider plans/strategi gene therapi overal follow recent hire dr john gray
page analyst certif import disclosur
longer term outlook remain neutral-r think success tripl combo alreadi price await clariti earlier stage
pipeline/addit valu driver pain/aatd/fsg program beta-thal/scd program crsp well recent ad program
recent acquisit exon
page analyst certif import disclosur
valuat risk
neutral valuat valu use discount cash flow analysi use wacc consist
commerci stage compani cover well termin growth rate downsid risk regulatori commerci setback potenti
emerg new competitor dilut financ beyond assum upsid risk pipelin success beyond alreadi account
forecast potenti acquisit premium current valuat
buy valuat price target per share previous base dcf analysi includ current
busi well probabl weight pipelin revenu assum discount rate termin growth risk suscept risk
appli entir biotech industri includ develop regulatori commerci manufactur financ ip risk specif includ
clinic risk concentr effort pioneer rnai therapeut howev accept risk scientif evid support
feasibl therapi still limit face skeptic base so-cal off-target effect activ interferon respons drug candid
demonstr efficaci laboratori set may translat well human clinic trial notabl unexpect safeti issu may aris lead program
could read-through entir platform/pipelin regulatori risk even develop stage candid clinic trial ultim success possibl
alni medicin approv global regulatori agenc given novelti rnai technolog human use agenc may requir addit
long-term data could delay potenti approv commerci risk limit experi commerci compani onpattro first commerci
product given natur diseas possibl may challeng identifi patient gain market share rel competitor
run commerci risk encount uncertainti commercializing/distribut onpattro drug competitor risk develop therapi
area treatment option limit possibl risk/benefit alni therapi may favor effect intens competit
pharmaceut market also antisens oligonucleotide/gen therapy/gen edit compani develop potenti competit medicin possibl
therapi could prove better safeti efficaci captur larger market share
neutral valuat pt assum alexion trade mean similar compani ep estim support risk-
adjust npv forward price-to-earnings compar analysi yield pt valu share use forward price-to-earnings multipl analysi look
price-to-earnings multipl select biotech pharma compani similar invest profil alexion compani trade consensu earn
estim offer averag ep compound-annual-growth-rate project ep compound-annual-growth-rate think l-t sustain franchis light
competit remain concern therefor believ share unlik trade premium peer appli mean multipl
non-gaap ep prior ep arriv pt net-present-valu npv analysi support p/e-bas pt includ
cash flow alxn base busi approv product current net cash discount rate termin growth rate upsid risk
upsid risk includ substanti larger expect growth soliri sale nmo larg growth pnh/ahu popul treatment
downsid risk downsid risk includ failur secur approv soliri nmo slower expect growth mg
neutral valuat pt base ep estim account recent clinic setback alzheim robust competit
horizon sma intrigu distinct pipelin believ trade discount peer larg cap biopharm compani multipl thu
assign price-to-earnings multipl also support risk-adjust npv forward price-to-earnings compar analysi yield pt upsid risk
unexpect success alzheim asset unexpect commerci growth rest pipelin downsid risk addit failur alzheim
asset tecfidera ipr decis
bgne buy valuat valu bgne per share use dcf-base valuat method valuat includ commerci product bgne
acquir celg part collabor includ abraxan revlimid vidaza well probability-adjust cash flow deriv drug
candid develop zanubrutinib tislelizumab pamiparib use discount rate consist commerci stage biotech
compani coverag termin growth rate appli termin year post patent expir compar similar compani
coverag risk risk valuat bgne includ regulatori commerci setback potenti emerg
new competitor and/or lower product sale expect risk intellectu properti risk manag execut misstep
neutral valuat base dcf analysi believ fairli valu forecast probability-weight revenu expens
assum discount rate termin growth rate risk suscept risk appli entir biotech industri includ
develop regulatori commerci manufactur financ ip risk specif includ commerci risk downsid risk medicin
page analyst certif import disclosur
target diseas small patient popul possibl compani may fail introduc new product market current product could produc less
revenu expect patient identif may slower expect product may receiv unfavor payor reimburs upsid risk possibl
market share assumpt conserv preval bmrn target diseas could prove larger current model clinic risk
downsid risk sever key pipelin product still clinic develop may delay clinic trial initi enrol unexpect safeti issu
efficaci lower expect upsid risk upcom data pivot data could prove efficaci look earlier stage studi
also possibl data competitor could look wors expect unexpect safeti issu could emerg could benefit bmrn competit
posit regulatori risk downsid risk clinic trial ultim success possibl bmrn medicin approv global regulatori
agenc given novelti certain medicin develop regulatori agenc may requir addit long-term data could delay potenti
approv upsid risk hand regulatori process could go faster smoothli expect ip risk downsid risk depend
intellectu properti protect control trade secret technolog innov inabl defend patent could result increas gener
competit addit compani may accus infring ip upsid risk compani could defend ip prevail legal proceed
celg neutral valuat valu celg use discount cash flow analysi util wacc termin growth rate valu
commerci product select upcom pipelin asset use sum-ofthe-part method valu celg whole upsid risk upsid risk rate
valuat celg includ celg obtain higher acquisit offer bmi share price increas current close price given share-bas compon
propos acquisit potenti faster regulatori approv expect investor three ozanimod lisocel would
increas present valu cvr downsid risk downsid risk valuat includ bmi share price declin current close price
buy valuat valu per share use dcf base valuat method valuat includ commerci product rubraca
ovarian cancer well probability-adjust cash flow deriv indic prostat cancer breast cancer use discount rate
consist commerci stage biotech compani coverag termin growth rate appli termin year post patent
expir compar similar compani coverag risk risk valuat includ regulatori
commerci setback potenti emerg new competitor /or lower product sale expect risk intellectu properti risk
manag execut misstep
buy valuat valu inc per share use dcf base valuat method valuat includ commerci product
cabometyx cometriq well probability-adjust cash flow deriv compani pipelin royalti out-licens program use
discount rate termin growth rate appli termin year post-assum gener entri cabozantinib risk risk valuat
inc includ regulatori commerci setback potenti emerg new competitor lower product sale expect
buy valuat price target per share base sum-of-the-part peak revenu analysi appli multipl
product global peak sale assum discount rate sum-of-the-part basi arriv galafold fabri diseas commerci
at-gaa pomp diseas po rest valuat come pipelin platform cash risk suscept risk
appli entir biotech industri includ develop regulatori commerci manufactur financ ip risk specif includ clinic
risk possibl could experi regulatori delay slower expect clinic trial neg data develop program addit
unexpect safeti issu could emerg particularli gene therapi program read-through broader pipelin regulatori risk clinic trial
ultim success possibl medicin approv global regulatori agenc galafold current acceler approv
us possibl compani success gener data convert full approv given novelti gene therapi technolog agenc
may requir addit long-term data could delay potenti approv ip risk ip use galafold treat fabri diseas monotherapi
expir us expir europ japan right patent possibl robust gene therapi
aav vector-gen therapi landscap rapidli evolv guarante access new develop technolog emerg
space manufactur risk manufactur complex biolog viral vector gene therapi complic expens possibl could
encount stumbl block along way particularli gene therapi program compani work translat academ program larger scale
manufactur headlin risk aav vector-gen therapi technolog wide follow public media possibl news technolog
unrel could lead downsid share
buy valuat price target per share base dcf analysi forecast probability-weight revenu expens
assum discount rate termin growth rate risk suscept risk appli entir biotech industri includ
page analyst certif import disclosur
develop regulatori commerci manufactur financ ip risk specif includ commerci risk possibl may fail
introduc new product market current product could produc less revenu expect patient identif may slower expect product
may receiv unfavor payor reimburs clinic risk sever key pipelin product still clinic develop may delay clinic trial
initi enrol unexpect safeti issu efficaci lower expect regulatori risk clinic trial ultim success possibl
gild medicin approv global regulatori agenc agenc may requir addit long-term data could delay potenti approv
ip risk depend intellectu properti protect control trade secret technolog innov inabl defend patent could
result increas gener competit addit compani may accus infring ip current sever legal proceed relat
product competitor risk hiv hcv busi repres signific amount total product sale mix could face increas competit
aggress competit face signific competit therapi develop includ liver diseas inflamm oncolog multipl compani
develop therapi could prove better safeti efficaci move faster market
gwph buy valuat pt gwph base sum-of-the-part sotp net-present-valu npv analysi includ probability-adjust
npv epidiolex dravet lennox-gastaut treatment-resist seizur technolog valu prior compani anticip
net cash posit use discount rate termin valu believ appropri similar-stag compani reflect current launch
trend ramp epidiolex sale assumpt increas peak sale assumpt addit follow success
indic increas probabl success estim refractori epilepsi base chang pt move
risk regulatori commerci setback potenti emerg new competitor financ becom cash flow posit biotech
compani carri risk need rais money market public and/or privat
buy valuat valu per share use probabl adjust free cash flow project jakafi iclusig olumi itacitinib
topic ruxolitinib use discount rate consist commerci stage biotech compani coverag termin growth rate
risk regulatori commerci setback potenti emerg new competitor lower product sale expect risk intellectu properti
risk manag execut
neutral valuat base blend averag sum-of-the-part sotp peak revenu analysi well probabl weight dcf
believ fairli valu peak revenu analysi appli multipl peak sale us eu assum discount rate
sum-of-the-part basi assum po fidanacogen elaparvovec po rest valuat deriv tech
platform valu cash dcf forecast probability-weight revenu expens assum discount rate termin
growth rate risk spark suscept risk appli entir biotech industri includ develop regulatori commerci manufactur
financ ip risk specif includ acquisit risk downsid risk valuat includ propos rog-sw acquisit close
due potenti regulatori reason upsid risk hand could get higher acquisit offer compani rog-sw commerci
risk downsid risk possibl luxturna may success penetr market underdiagnos patient identif may slower
expect payor dynam gene therapi gene edit therapi still emerg luxturna may receiv unfavor payor reimburs upsid
risk possibl market share assumpt conserv preval target diseas could prove larger current
model clinic risk risk downsid includ delay clinic trial initi enrol unexpect safeti issu may aris efficaci
lower expect upsid risk upcom pivot data could efficaci look earlier stage studi also possibl data
competitor could look wors expect unexpect safeti issu could emerg could benefit competit posit regulatori risk
downsid risk even clinic trial ultim success possibl onc medicin approv global regulatori agenc given
novelti technolog agenc may requir addit long-term data could delay potenti approv upsid risk hand regulatori
process could go faster smoothli expect
orilissa sale grow faster expect approv indic potenti acquisit downsid risk regulatori commerci setback potenti
emerg new competitor financ
neutral valuat valu use discount cash flow analysi though valuat includ commerci product nerlynx well
probability-adjust cash flow potenti label expans use wacc consist commerci stage compani cover
well termin growth rate upsid risk upsid risk valuat includ higher-than-expect volum uptak emerg new
page analyst certif import disclosur
pipelin agent valuat potenti acquisit premium downsid risk downsid risk valuat includ regulatori
commerci setback potenti emerg new competitor lower product sale expect
neutral valuat pt assum trade non-gaap ep estim support risk-adjust npv
forward price-to-earnings compar analysi yield pt upsid risk substanti faster expect growth eylea/dupixent/libtayo sale setback
competit trial downsid risk failur secur approv eylea/dupixent/libtayo addit indic
buy valuat valu per share use dcf-base valuat method reduc sale forecast adcetri
slightli increas near-term sg cost also increas po ev tv recent reflect increas
confid two program recent data mention valuat includ commerci product adcetri well probability-adjust cash flow
deriv compani pipelin use discount rate consist commerci stage biotech compani coverag
termin growth rate appli termin year post-assum adcetri biosimilar entri risk risk valuat includ
regulatori commerci setback potenti emerg new competitor /or lower product sale expect risk intellectu properti
risk manag execut misstep
neutral valuat base dcf analysi believ fairli valu forecast probability-weight revenu expens
assum discount rate previous termin growth rate po previous cf tripl therapi po
gene therapi risk suscept risk appli entir biotech industri includ develop regulatori commerci
manufactur financ ip risk specif includ clinic risk pipelin apart cystic fibrosi earli stage sever
compound early-to-l preclin phase possibl addit research conduct front thu far addit patient may
present cf program respect hemoglobinopathi risk upsid includ better data anticip -thal scd and/or
rapid advanc clinic either program addit rapid progress earlier stage pipelin also repres upsid risk risk
downsid includ delay clinic trial initi unexpect safeti issu may aris efficaci lower expect beyond lead
program cf pain scd/ thal vrtx pipelin preclin possibl could delay clinic trial initi regulatori risk
downsid clinic trial ultim success possibl vrtx medicin approv global regulatori agenc given novelti
technolog agenc may requir addit long-term data could delay potenti approv upsid hand fda focus
rapidli advanc approv novel innov therapi possibl regulatori process could go faster smoothli expect ip
risk upsid vrtx cf offer consist multipl compon protect last expir compon drug mean
compani next-gen corrector cf enjoy ip protect well compani in-licens agreement place pursuant
share right mrna therapeut treatment cf result also co-exclus right crsp ip around
technolog platform downsid crispr landscap rapidli evolv guarante access new
develop technolog emerg space competitor risk upsid pioneer cf program continu make long stride
cf space two next-gener tripl cocktail recip enter market acquir glpg clinical-stag cf program less than-
impress dual tripl therapi pose threat yet vrtx offer downsid technolog wide follow public media
possibl news technolog unrel /crsp could lead either upsid downsid share develop therapi
area entrench standard care therapi use also gene therapy/gen edit compani develop potenti competit medicin
possibl therapi could prove better safeti efficaci move faster market respect pain relief drug
could direct competit opioid steroid nsaid gener howev establish competit efficaci safeti
inhibitor clinic trial could creat sizeabl market non-opioid-bas pain manag drug
page analyst certif import disclosur
total cost expens
interest incom net
total incom
incom tax
compani report guggenheim secur llc estim
page analyst certif import disclosur
mm except per share data
factset consensu
incom tax
factset consensu
cog tot prod sale
 tot revenu
sg tot revenu
compani report guggenheim secur llc estim
page analyst certif import disclosur
revenu
revenu
non-gaap ep exclud stock-comp item
revenu
consensu
consensu
compani report guggenheim secur llc estim
page analyst certif import disclosur
amort intang
total incom expens
net incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
royalti sale
royalti
gain sale right
adjust tax provis
non-gaap ep exclud stock-comp item
consensu
consensu
compani report guggenheim secur llc estim
page analyst certif import disclosur
mm except per share data
royalti revenu
factset consensu
total incom expens net
incom tax
net incom attribut
factset consensu
cog
sg
tax
non-gaap net incom attribut
factset consensu
cog tot prod sale
 tot revenu
sg tot revenu
compani report guggenheim secur llc estim
page analyst certif import disclosur
amort acquir intang asset
acquisition-rel charg restructur
total cost expens
interest invest incom net
compani report guggenheim secur llc estim
page analyst certif import disclosur
sg product sale
 revenu
cog product sale
soe sg
compani report guggenheim secur llc estim
page analyst certif import disclosur
cash equival
properti plant equip net
short-term borrow current portion long-term debt
accru expens current liabil
long-term debt net discount
compani report guggenheim secur llc estim
page analyst certif import disclosur
chang
flow oper
account payabl oper liabil
flow invest activ
increase/decreas secur intang fin asset
flow financ activ
payment treasuri share
net payment/proce show term borrow
proce long term debt issu
princip repay current portion long-term debt
effect currenc rate chang cash cash equival
compani report guggenheim secur llc estim
page analyst certif import disclosur
